BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of...
VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure...
Company to host webcast on Monday, August 16th at 8:30 am ETNEVE ILAN, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) --...
ODD Follows RMAT Designation Granted to ALLO-715 by the U.S. Food and Drug Administration in Multiple Myeloma PatientsPhase 1 Data...
Promotion Recognizes Skilled Leadership and Contributions to MIMEDX’s Continued Growth MARIETTA, Ga., Aug. 12, 2021 (GLOBE NEWSWIRE) -- MiMedx Group,...
Clinical Trials Continue Despite COVID-19 Restrictions Fremont, CA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc., a clinical...
Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 presented at ASCO Annual Meeting; on track to...
TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (Frankfurt:31R), a...
Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter...
New Partnership will help Fluo Labs Bring to Market its Medical Device, Designed to Improve Hay Fever Symptoms via Light...
–1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA–SHANGHAI, China, and REDWOOD CITY, Calif.,...
1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLASHANGHAI, China and...
Conference Call and Webcast Today at 4:30 p.m. Eastern TimeSAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:...
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES VANCOUVER, British Columbia, Aug. 12, 2021...
Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the U.S. in Q4 2021Validive® Phase 2b/3 VOICE Trial on Track...
Continued Company investment across our iPSC platforms, programs, and manufacturingLead program, CNTY-101, remains on track for IND filing in mid-2022Recent...
MURRAY, Utah, Aug. 12, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that...
SAN CARLOS, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. , a developer of cellular and cell-derived therapeutics for the...
Company to Host Conference Call Today at 9 a.m. EDTCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE)...
IND filing for wholly owned gene therapy program, SEL-302 (MMA-101, in combination with ImmTOR) in methylmalonic acidemia (MMA) expected during...
